Acute Effect of Local Vibration in Stroke Patients
Investigation of the Acute Effect of Local Vibration Application on Gait and Balance in Stroke Patients
Kırıkkale University
20 participants
Jan 1, 2025
INTERVENTIONAL
Conditions
Summary
The aim of the research is to examine the acute effect of local vibration application on gait and balance in stroke patients.
Eligibility
Inclusion Criteria7
- years old diagnosed with stroke
- Being diagnosed with ischemic or hemorrhagic stroke,
- Not having cooperation and communication problems,
- Stroke individuals with gastrosoleus spasticity, those with a MAS score of 2 or below,
- Those who score 0-3 on the Modified Rankin Scale.
- People weighing less than 150 kilos
- Patients who can walk independently (with an assisted device if they use an assistive device)
Exclusion Criteria5
- Have undergone surgery or botox for spasticity in the last 6 months,
- Those with joint contracture,
- Having a neurological disease other than stroke that may affect the patient's ability to walk and stand independently, or having pain in the lower extremity joints and a history of fractures in the lower extremities in the last 6 months,
- Having spasticity that prevents sole contact
- Patients who do not agree to participate in the study and do not give written consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Local vibration (LV) application will be made with the Vibrasens© (Techno Concept, Mane, France) device. Vibrasens© is a mechanical vibrator that produces transcutaneous vibration stimulations used in sensory-motor rehabilitation. Vibrasens©; It is a non-invasive, therapeutic device. Vibrasens© includes 1 pilot unit, 1 manual vibrator VB200, 4 flat skin contactors for tendon application, 4 round skin contactors for skin application, 1 power supply, 1 user manual and 1 protocol guide. LV application will be applied to the most swollen part of the spastic medial gastrocnemius muscles in the treatment group for 10 minutes. LV will be applied to one of the treatment groups at a frequency of 80Hz with an amplitude of 1 mm.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06610994